TORONTO, June 11 /CNW/ - Viventia Biotech Inc., a privately held
biopharmaceutical company advancing a portfolio of novel antibody products for
the treatment of cancer, today announced it has initiated patient dosing for
its Phase I clinical trial of VB6-845. Designed for systemic use against
metastatic cancers, VB6-845 is a humanized antibody fragment targeting EpCAM
fused with the Company's proprietary deimmunized form of the cytotoxic protein
The Phase I dose-escalation trial will enroll 40-50 patients with
advanced epithelial cancers that are EpCAM positive and is designed to
establish the safety and preliminary efficacy of this novel cytotoxic
conjugate. The study will be conducted as a solid tumors "all comers" trial,
so that accrual can be expedited and a range of responses obtained.
"Our unique approach to creating cancer drugs has yielded a novel
antibody-based therapeutic with the potential to be safer than traditional
cancer treatments while attacking cancers in their most lethal form, once they
have metastasized," said Dr. Nick Glover, President and CEO of Viventia
Biotech. "We look forward to advancing this Phase I trial and evaluating the
safety and early efficacy results expected later this year."
VB6-845 has demonstrated effective cancer cell killing properties in
pre-clinical tests. A full array of animal efficacy studies and safety studies
of VB6-845 for the treatment of ovarian cancer and other solid tumors has been
completed. In animal xenograft studies, VB6-845 elicited 100% complete cures
of established ovarian tumors. VB6-845 has been shown to be safely tolerated
in both primate and rodent animal safety studies.
Viventia is expanding its late-stage pipeline with additional novel
anti-cancer therapeutics consisting of human antibodies obtained from its
proprietary antibody generation platform Hybridomics(TM) conjugated to its
proprietary cytotoxic protein Bouganin. Viventia retains full global product
rights to all of its drug candidates and technology platforms. The Company's
business development efforts are focused on identifying and selecting a
partner capable of complementing Viventia's development expertise with global
sales, marketing and commercialization capabilities.
Originally isolated from the Amazonian tropical shrub, Bougainvillea
spectabilis, Bouganin is a novel ribosome inactivating protein from an
emerging class of novel anti-cancer and anti-viral agents isolated from
various plant species. Bouganin has a benign safety profile against normal,
healthy cells, but has potent anti-cancer activity against many types of
epithelial tumors. Viventia has further maximized the therapeutic potential of
this promising cytotoxic protein through deimmunization, a method that renders
the plant protein invisible to the immune system, thus facilitating systemic,
multi-dose therapeutic strategies. Bouganin is being developed by Viventia
Biotech as a key component in its anti-metastatic cancer program.
About Viventia Biotech:
Viventia Biotech Inc. is a biopharmaceutical company developing Armed
Antibodies(TM), powerful and precise anti-cancer drugs that combine cytotoxic
protein payloads with the highly precise tumor-targeting characteristics of
monoclonal antibodies to overcome various forms of cancer. Viventia's lead
product, Proxinium(TM), is undergoing a global Phase III clinical trial for
the treatment of head and neck cancer. Viventia is also developing
Vicinium (TM), which is undergoing a Phase II clinical study for the treatment
of bladder cancer. The Company has created a portfolio of follow-on
antibody-based drug candidates and has a discovery engine to provide a rich
and sustainable long-term pipeline.
For further information:
For further information: James Smith, Tel. (416) 815-0700 x 229, Fax.
(416) 815-0080, Email: email@example.com; www.viventia.com;